期刊文献+

前列腺癌组织中p27、bcl-2蛋白的表达水平及临床意义 被引量:5

Clinical significance and expression of p27,bcl-2 proteins in prostatic carcinoma
下载PDF
导出
摘要 目的探讨不同前列腺组织中p27、bcl-2蛋白的表达水平及临床意义。方法收集活检或手术切除前列腺组织标本,按病理诊断分为前列腺癌组30例、前列腺增生组20例;其中前列腺癌组又分为高分化组(13例)、中低分化组(17例)。应用免疫组织化学SP法检测上述标本中p27、bcl-2蛋白的表达。结果 p27蛋白在前列腺癌组织中的阳性表达率(23.3%)显著低于前列腺增生组织中的阳性表达率(85.0%),差异具有统计学意义(P<0.05);bcl-2蛋白在前列腺癌组织中的63.3%阳性率,显著高于前列腺增生组织中的10.0%阳性率,差异具有统计学意义(P<0.05);p27在前列腺癌高分化组的阳性表达率(46.1%)显著高于中低分化组(5.9%)(P<0.05),bcl-2蛋白在前列腺癌高分化组的阳性表达率(38.5%)显著低于中低分化组(82.4%)(P<0.05)。结论 p27、bcl-2蛋白的异常表达与前列腺癌的发生发展密切相关,检测p27和bcl-2蛋白水平在前列腺癌鉴别及临床预后具有一定的价值。 Objective To explore the expression of p27 and bcl-2 proteins in different prostate tissue and their clinical significances.Methods In this study,about 30 prostatic carcinoma patients and 20 benign prostatic hyperplasia patients were collected by biopsy and exairesls,while 30 prostatic carcinoma patients were divided to high differentiated group(n=13)and medium-poor entiated group(n=17).The expressions of p27 and bcl-2 protein were measured by SP immnohistochemical.Results The positive expression rates of p27 was 23.3%in prostatic carcinoma,which was significantly lower than those of benign prostatic hyperplasia(P<0.05).The positive expression rates of bcl-2 was63.3%in prostatic carcinoma,which was significantly higher than those of benign prostatic hyperplasia(P<0.05).The level of p27 in the group of well-differentiated was 46.1%,which was significantly higher than those in the medium-poor differentiated group(5.9%)(P<0.05).The bcl-2 positivelevel in well-differentiated prostatic carcinoma was38.5%,which was significantly lower than those in the medium-poor differentiated group(82.4%)(P<0.05).Conclusion The deregulationof p27 and bcl-2 protein may play important roles in tumori genesis and progression of prostatic carcinoma.Detections of p27 and bcl-2 protein are useful for clinical prognosis.
作者 李正义 李颖毅 罗成 袁文兵 LI Zheng-yi;LI Ying-yi;LUO Cheng(Urology Surgery,Shaanxi Baoji People′s Hospital,Baoji 721000,China)
出处 《中国实验诊断学》 2019年第6期954-956,共3页 Chinese Journal of Laboratory Diagnosis
基金 陕西省自然科学基金项目(2013JM4016)
关键词 前列腺癌 免疫组织化学 P27 BCL-2 Protaste carcinoma Immunohistochemistry p27 bcl-2
  • 相关文献

参考文献3

二级参考文献32

  • 1徐妙生,何艳姣,刘朝霞,李光.前列腺癌组织bcl-2、p53、P504S及34βE12蛋白的表达水平[J].首都医科大学学报,2007,28(4):538-541. 被引量:3
  • 2Yan WF, Wu G, Sun PC, et al. P53 mutations occur more commonly than KRAS mutations in colorectal adenoma[J]. Int J Clin Exp Med,2015,8 : 1370-1375.
  • 3Wang G, Reed E, Li QQ. Apoptosis in prostate cancer: progressive and therapeutic implications(Review)[J]. Int J Mol Med,2004,14:23-34.
  • 4Baranwal S, Alahari SK. Molecular mechanisms controlling E- cadherin expression in breast cancer[J]. Biochem Biophys Res Commun, 2009,384 : 6-11.
  • 5Crawford LV, Pim DC, Lamb P. The celluar protein p53 in human tumor[J]. Mol Biol Med, 1984,2: 261-272.
  • 6Pisters LL, Pettaway CA: Troncoso P, et aL Evidence that transfer of functional p53 protein results in increased apoptpsis in prostate cancer[J]. Clin Cancer Res, 2004,10: 2587-2593.
  • 7Levine AJ,Finlay CA, Hinds PW. P53 is a tumor suppressor gene[J]. Cell, 2004,116 : $67-69.
  • 8Ostrakhovitch EA, Olsson PE, Jiang S, ct al. Interaction of metallothionein with tumor suppressor p53 protein[J]. FEBS Lett, 2006,580: 1235-1238.
  • 9Hara T, Miyazaki H, Lee A, et al. Androgen receptor and invasion in prostate cancer [J]. Cancer Res, 2008, 68: 1128-1135.
  • 10Yuan J, Kroemer G. Alternative cell death mechanisms in development and beyond[J3. Genes Dev, 2010,24 : 2592-2602.

共引文献10

同被引文献50

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部